Objectives: Evaluation of a high-dose-step-down strategy for caspofungin treatment in an 2 experimental model of advanced stage of invasive pulmonary aspergillosis. 3
INTRODUCTION 29
Invasive Pulmonary Aspergillosis (IPA) is a life-threatening fungal infection observed in 30 severely immunocompromised patients. At present antifungal treatment has changed with the 31 introduction of broader spectrum azoles and the echinocandins. In contrast to amphotericin B 32 and the azoles, the echinocandins, with caspofungin as the first approved member, do not act 33 on the cell membrane but on the cell wall (11, 12) . The echinocandins inhibit the 1,3-β-D-34 glucan synthesis, an essential molecule which provides osmotic stability to fungi and is 35 essential in growth and division (11, 12) . As 1,3-β-D-glucan is not found in mammalian cells, 36 inhibition of this synthesis in fungi is highly specific resulting in high tolerability of the 37 echinocandins (11), which explains why until now, no serious side-effects of caspofungin 38 have been published, and the drug seems to have an excellent safety profile (4). Caspofungin 39 has been demonstrated to be effective as salvage therapy in patients with documented invasive 40 aspergillosis, and as empiric therapy in patients with persistent fever and neutropenia (10, 18) . 41
Although caspofungin seems to have a favourable therapeutic effect in neutropenic patients 42 with invasive aspergillosis, animal studies remain necessary to evaluate the full efficacy of 43 this drug. Our earlier study already showed the therapeutic efficacy of caspofungin in a 44 clinically relevant Aspergillus fumigatus infection model in transiently neutropenic rats (17) . 45
Treatment was started at 16 hours after inoculation, when fungal hyphal growth was 46 established. Caspofungin at 4 mg/kg/day administered for 10 days resulted in 100 % rat 47 deviations, it was assumed that inhibition or loss of the sample had occurred either during 104 DNA isolation or during PCR. In such cases, the DNA isolation and TaqMan analysis were 105 repeated till the internal control was within the normal range. 106
The galactomannan concentrations in both serum and left lung were determined by the 107 commercial Platelia Aspergillus system of Bio-Rad (Platelia Aspergillus, Bio-Rad, Marnes-la-108
Coquette, France). To obtain quantitative results this system was modified in our lab as 109 described before (3). 110
Dissected organs from all deceased animals were cultured to exclude bacterial super 111
infections. 112 113

Pharmacokinetics of antifungal agents 114
The pharmacokinetics of caspofungin were determined after multiple-dose administrations in 115 uninfected neutropenic rats. In rats receiving 3 doses of 10 mg/kg/day serial blood samples 116 were taken at 5 minutes, 1h, 2h, 4h, 6h, 8h, 12h and 24h after the third dose by retro-orbital 117 puncture under CO 2 -anaesthesia. In rats receiving 3 doses of 10 mg/kg/day followed by 7 118 doses of 4 mg/kg/day serial blood samples were taken at the same time-points after the tenth 119 dose. Plasma samples were obtained from three rats at each time-point, and the concentration 120 of caspofungin was assessed by standard large plate agar diffusion as described before (17) . 121
The area under the plasma concentration versus time curve (AUC 24h ) was calculated using the 122 log-linear trapezoid rule. 123
124
Toxic side effects of Caspofungin 125
To determine toxic side effects of caspofungin doses on the kidneys or the liver, renal and 126 hepatic functions were monitored. This was done by sampling blood on day 6 and day 13 after 127 starting caspofungin treatment. In these serum samples serum creatinine (CREAT) and blood 128
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on August 29, 2017 by guest http://aac.asm.org/ Downloaded from urea nitrogen (BUN) levels were determined to assess the renal functions while serum alanine 129 aminotransferase (ALAT) and aspartate aminotransferase (ASAT) were measured to assess 130 the hepatic functions. The same parameters were determined for a healthy control group, 131 consisting of 35 rats, to calculate the normal values for this rat strain. Mild toxicity was 132 defined when levels for either one of these parameters was more than 3 times the upper limit 133 of normal (3 times the 95 percentile boundary of the healthy control group), severe toxicity 134 was defined as levels higher than 5 times the upper limit of normal. 135
136
Statistical analysis 137
Kaplan-Meier survival curves were generated and the differences in rat survival rate assessed 138 with log rank test. Normality of ALAT, ASAT, BUN and UREUM was determined with the 139 Shapiro-Wilk test. 140 141
142
RESULTS 143
Effect of antifungal treatment on rat survival 144 During the treatment period of 10 days rats were persistently neutropenic (granulocyte counts 145 <0.1*10 9 /L), and the 10 day period after termination of treatment neutrophil numbers 146 gradually rose. As shown in figure 1, untreated control rats all died between day 5 and day 9 147 after fungal inoculation. Treatment for 10 days with caspofungin 4 mg/kg/day started at 16 h 148 after fungal infection, the time at which hyphal growth in the left lung was established, 149 resulted in therapeutic efficacy, with 100% survival of rats. Delay of treatment till 24 h after 150 fungal infection resulted in a slight but not significant reduction in therapeutic effect 151 (p=0.3918) providing 93% rat survival rate. When treatment was further delayed until 72 h 152 after infection when rats had advanced stage of invasive pulmonary aspergillosis caspofungin 153
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on August 29, 2017 by guest http://aac.asm.org/ Downloaded from was still effective compared to untreated control rats (p<0.0001). However only 27 % rat 154 survival rate was obtained, which therapeutic effect was significantly less than efficacy when 155 treatment was started at 24 h or 16 h after fungal inoculation (p<0.0001 for both). To evaluate 156 if a higher dose of caspofungin dosage would compensate for the limited therapeutic effect 157 related to late start of treatment a dose of 10 mg/kg/day was administered for 10 days. We 158 observed that an increase in caspofungin daily dose from 4 mg/kg to 10 mg/kg resulted in a 159 significant increase in therapeutic effect (p=0.0159) being a 67 % rat survival. Finally, to 160 investigate whether this relatively high dose of 10 mg/kg/day was needed throughout the 161 entire treatment period we investigated whether with a high-dose-step-down schedule a 162 similar efficacy could be achieved. As shown in figure 1 a high dose of caspofungin 10 163 mg/kg/day for only 3 days followed by 4 mg/kg/day for 7 days did not differ from the 10 164 mg/kg/day continuous schedule for 10 days (p=0.9147). 165
Apparently a high dose of caspofungin during the first three days of the treatment schedule 166 only was essential. The AUC 24h of caspofungin determined after the third dose in rats 167 receiving 3 doses of 10 mg/kg/day caspofungin appeared to be 549.3 µg.h/ml. The AUC 24h of 168 caspofungin determined after the tenth dose in rats receiving 3 doses of 10 mg/kg/day 169 followed by 7 doses of 4 mg/kg/day was 114 µg.h/ml. 170
171
Toxic side effects of the dosing schemes 172
In order to investigate whether increase in dosage of caspofungin was well tolerated in rats we 173 determined the renal and hepatic functions of the treated animals. Serum CREAT, BUN, 174 ALAT and ASAT were determined. As shown in table 1, none of the applied caspofungin 175 dosage schemes resulted in alarming high levels of either parameter, even in the severely ill 176 infected neutropenic animals. Although kidney and liver functions were unimpaired, it was 177 observed that animals receiving the relatively high dose of caspofungin 10 mg/kg/day became 178
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These effects were found in both the infected as the non-infected control group. Rats 180 recovered within one or two hours. Effects were strongest after the first dose, but became less 181 intense each following dose. 182
183
Effect of antifungal treatment on fungal burden in rats 184
The CE counts in infected left lungs and GM concentrations in infected left lungs and sera of 185 surviving rats are presented in figures 2 and 3. As shown in figures 2A and B, in untreated 186 infected rats mean log CE counts and mean log GM concentrations increased over time in the 187 first days after fungal infection. However, the fungal burden in terms of DNA or GM did not 188 decrease during caspofungin therapy when started at 72 h after fungal infection. Even in rats 189 treated with caspofungin dosage schedules that resulted in a significant rat survival rate of 190 67%, the fungal burden in the left lung still remained high. Figure 3 shows that in untreated 191 infected control rats the mean log GM concentration in serum increased over time from 192 undetectable at day 1 to 0.98 at day 6. In caspofungin-treated animals GM levels further 193 increased with peak levels at day 9 (6 days after start of treatment). to undetectable levels after 11 days post infection. In the current study we investigated 208 whether caspofungin was also effective in advanced stage of invasive pulmonary 209 aspergillosis, which may be a clinically more relevant endpoint because the diagnosis of 210 invasive pulmonary aspergillosis is often made at a late stage of disease. To this aim 211 antifungal treatment in rats was delayed from 16 h to 24 h or 72 h after fungal inoculation. 212
Although efficacy of caspofungin treatment decreased with increase in severity of infection, 213 this decrease in efficacy could be partly compensated for by increasing the dose of 214 caspofungin from 4 to 10 mg/kg/day. A regimen of caspofungin in which the caspofungin 215 dose was increased during only the first three days of treatment was essential to increase 216 therapeutic efficacy. 217 A relatively high AUC 24h (549.3 µg.h/ml) was observed after the three-day high dose of 10 218 mg/kg/day caspofungin. The AUC 24h value of 114 µg.h/ml obtained after the last dose of 4 219 mg/kg/day at day 10 of the high-dose-step-down schedule was comparable to the AUC 24h 220 value of 91.8 µg.h/ml obtained after a single 4 mg/kg/day dose as published before (17). At 1 221 h after administration of the last dose of 4 mg/kg/day dose at day 10 of the high-dose-step-222 down schedule, the plasma concentration was 2-fold higher for compared to the single 4 223 mg/kg/day dose (17), at 12 h after administration the plasma levels were similar. The AUCs 224 presented here were determined in neutropenic non-infected animals which could result in an 225 underestimation of the real AUC as demonstrated by Groll et al. for anidulafungin, another 226 member of the echinocandin class (9). It should be noted that the AUC 24h value obtained after 227 10 mg/kg/day caspofungin was not proportionally increased, based on the increase in dosage, 228 The benefit of a relatively high AUC 24h in the first phase of the therapy was also observed in 231 man by Stone et al. (15) . They showed that a loading dose on day one generates a higher drug 232 concentration in plasma during the initial days of therapy; without this dose the mean 233 concentration in the first days is below the target concentration (15). This could explain why 234 high-dose-step-down regimen was more efficacious. 235
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The increase in efficacy with higher doses of caspofungin in severely infected rats was only 236 observed by rat survival and lower concentrations of galactomannan in serum. At the same 237 time decrease in fungal burden in the lung in terms of amount of DNA or GM in the left lung 238 was not observed. Both GM, as constitute of the fungal cell wall (8) with the echinocandins anidulafungin (previously known as LY303366) and micafungin (6, 7, 245 14) . In Clemons' study (6) 90% of the non-infected mice treated with anidulafungin 50 246 mg/kg/day had died after 3 days of treatment. The toxicity of anidulafungin appeared to be the 247 result of drug interactions with immunosuppressive agents like cortisone, hydrocortisone or 248 triamcinolone (6). The nature of the toxicity for the echinocandins still remains unclear, since 249 no histological evidence for the cause of death in the anidulafungin treated animals was found 250 (6). In our study hepatic and renal functions were monitored, and these values all remained in 251 the normal range even with the relatively high dosage of caspofungin. The nature of this 252 observed side effect may be related to the rapid absorption of the drug when it is given 253 Serum creatinine (CREAT), blood urea nitrogen (BUN), alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) were determined at day 6 and day 13 after fungal inoculation in uninfected control rats, cyclophosphamide (cyclo)-induced neutropenic rats and cycloinduced neutropenic infected rats receiving various doses of caspofungin (CAS). Doses were 10 days 4 mg/kg/day (10*4), 3 days 10 mg/kg/day followed by 7 days 4 mg/kg/day (3*10 + 7*4) or 10 days 10 mg/kg/day (10*10). Mild toxicity was defined as parameter levels exceeding the 3 times upper limit boundary, severe toxicity when levels exceeded the 5 times upper limit boundary. For reference the upper limit is stated as well.
1 ND: the renal and hepatic functions could not be determined as all rats had died. 
